07:00 , Oct 11, 2004 |  BC Week In Review  |  Company News

Chiesi Farmaceutici SpA, Eli Lilly, Icos, Laboratoires Fournier SA, Recordati SpA sales and marketing update

Chiesi Farmaceutici SpA , Parma, Italy   Eli Lilly and Co. (LLY), Indianapolis, Ind.   Icos Corp. (ICOS), Bothell, Wash.   Laboratoires Fournier SA , Dijon, France   Recordati SpA , Milan, Italy   Fournier's...
07:00 , Oct 8, 2004 |  BC Extra  |  Company News

Fournier discloses marketing deals

Laboratoires Fournier (Dijon, France) said its Fournier Pharma division received a license from Recordati (Milan, Italy) to market its Zanidip lercanidipine oral calcium-channel blocker to treat hypertension in Indonesia, Vietnam and other Asian countries. Fournier...
08:00 , Mar 8, 1999 |  BC Week In Review  |  Clinical News

Biovail Corp. International regulatory update

Canada granted marketing approval for BVF's Brexidol piroxicam-beta-cyclodextrin, a non-steroidal anti-inflammatory drug (NSAID) to treat mild to severe acute pain. BVF's Crystaal division will market Brexidol in Canada Biovail Corp. International (BVF), Toronto, Ontario  ...
08:00 , Mar 23, 1998 |  BC Week In Review  |  Company News

Biovail Corp. International, Chiesi Group deal

BVF’s Crystaal Corp. subsidiary received an exclusive license to market in Canada Chiesi’s Brexidol piroxicam, a non-steroidal anti-inflammatory agent to relieve mild to severe acute pain. Brexidol has the same active ingredient as Pfizer’s Feldene....